miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review

Maria Teresa Di Martino,Mariamena Arbitrio,Daniele Caracciolo,Alessia Cordua,Onofrio Cuomo,Katia Grillone,Caterina Riillo,Giulio Caridà,Francesca Scionti, Caterina Labanca,Caterina Romeo,Maria Anna Siciliano,Maria D'Apolito,Cristina Napoli,Martina Montesano,Valentina Farenza, Valentina Uppolo, Michele Tafuni,Federica Falcone, Giuseppe D'Aquino,Natale Daniele Calandruccio,Francesco Luciano,Licia Pensabene,Pierosandro Tagliaferri,Pierfrancesco Tassone

Molecular Therapy - Nucleic Acids（2022）

引用 22|浏览10

暂无评分

摘要

Among deregulated microRNAs (miRs) in human malignancies, miR-221 has been widely investigated for its oncogenic role and as a promising biomarker. Moreover, recent evidence suggests miR-221 as a fine-tuner of chronic liver injury and inflammation-related events. Available information also supports the potential of miR-221 silencing as promising therapeutic intervention. In this systematic review, we selected papers from the principal databases (PubMed, MedLine, Medscape, ASCO, ESMO) between January 2012 and December 2020, using the keywords "miR-221" and the specific keywords related to the most important hematologic and solid malignancies, and some non-malignant diseases, to define and characterize deregulated miR-221 as a valuable therapeutic target in the modern vision of molecular medicine. We found a major role of miR-221 in this view.

查看译文

关键词

miR-221,miR-221/222,miRs,miR,microRNA,miR therapeutics,cancer,NASH,sarcomas,myeloma,breast cancer,gastrointestinal cancer,lung cancer,hepatocellular carcinoma,ovarian cancer,cervical cancer,endometrial cancer,pancreatic cancer,biliary tract cancer,prostate cancer,glioblastoma,urogenital cancer,bladder cancer,renal cell carcinoma,gynecological cancers,melanoma,solid cancers,hematological diseases,neuropathy,demyelinating diseases,pharmacokinetics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要